Cancer-Fighting antibiotic trial targets precancerous blood cells
NCT ID NCT07209371
Summary
This study is testing whether a short course of the antibiotic rifaximin can reduce abnormal blood protein levels in people with IgA MGUS, a condition that can sometimes turn into cancer. Fifty adults with IgA MGUS will be randomly assigned to either take the antibiotic pills for two weeks or receive no treatment, with regular blood tests to monitor results. The goal is to see if the drug can kill or reduce the precancerous cells and potentially lower the future risk of cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.